Fig. 5

CWP232291 blocks the growth of prostate cancer cells and primary cells derived from castration-resistant prostate cancer patients. a 22Rv1 and VCaP cells were exposed to CWP232291 (0–10 μM) and docetaxel (0–10 μM) for 72 h. Cell viability was determined using CellTiter Glo® (means ± SD, n = 3). b Docetaxel-resistant DU145 and parental DU145 cells were exposed to CWP232291 (0–10 μM) and docetaxel (0–10 μM) for 72 h. Cell viability was determined using CellTiter Glo® (means ± SD, n = 3). c Primary prostate cancer cells derived from patients with castration-resistant prostate cancer were exposed to CWP232291 (0–10 μM) for 72 h. Cell viability was determined using CellTiter Glo® (means ± SD, n = 3)